• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ACW

ACTINOGEN MEDICAL LIMITED - News & Media

3.70% ! 2.8¢
Market Cap $88.91M  !
Healthcare Biotechnology
Add to My Watchlist

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel... Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long term cognitive health.More

Recently Updated

Corporate Spotlight

Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives.
View the full Corporate Spotlight arrow Created with Sketch.

Actinogen reaches 100th participant milestone

Articles & Videos

With 100 enrolled and $13.8M in hand, Actinogen's Xanamem timeline is in full swing

Actinogen Medical (ASX:ACW) has this week enrolled its 100th participant for its @pivotal” XanaMIA phase 2b/three trial for Xanamem, its investigational drug designed to treat the cognitive decline in Alzheimer’s disease.Listen to the HotCopper podcast for in...

30 Jun 2025 09:47 (AEST)

Xanamem: Alzheimer's breakthrough set for 2025, 2026

The search for an effective treatment for neurological conditions like Alzheimer’s disease remains one of the most urgent challenges in global healthcare. In 2025, Australian biotech company Actinogen Medical Ltd (ASX:ACW) is making significant strides in tackling this issue with ...

05 Mar 2025 11:00 (AEDT)

Actinogen reports busy 6 months as development of Xanamem molecule ramps up

Actinogen Medical Ltd said it had pared back net losses in the 6 months to December 2024, a development activity increased

24 Feb 2025 16:59 (AEDT)

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 

25 Nov 2024 03:00 (AEDT)

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

Actinogen Medical Ltd has received a $9M R&D rebate from the Australian Taxation Office which will fund its activities through to mid-2026

12 Nov 2024 13:41 (AEDT)

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.

24 Sep 2024 12:22 (AEST)

Xanamem shows further depression improvements four weeks after 6-week treatment course

Actinogen (ASX:ACW) has reported success in using its novel antidepressant Xanamem to mitigate the symptoms of major depression based on a daily 10mg dose.

26 Aug 2024 10:36 (AEST)

Actinogen Medical weighs in on its latest results to market

Actinogen Medical (ASX:ACW) recently announced results from its XanaCIDD Phase 2a trials, which demonstrated the drug's significant clinical and statistical benefits over a placebo in treating depression.

13 Aug 2024 10:33 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
2.8¢ 		Change
0.001(3.70%) 		Mkt cap ! $88.91M
Open High Low Value Volume
2.8¢ 2.8¢ 2.7¢ $12.00K 444.5K

Buyers (Bids)

No. Vol. Price($)
1 530460 2.7¢
 

Sellers (Offers)

Price($) Vol. No.
2.8¢ 1529473 6
View Market Depth
Last trade - 16.10pm 09/09/2025 (20 minute delay) ?
ACW (ASX) Chart

Top Stories

Nanocap Livium pops +30% on purchase of REE extraction technology from Melb Uni

Livium has become one of the nanocaps juicing hard, with shares up nearly +30% as the company inks a deal alongside Melbourne University.
Listen: HotCopper Wire Podcast 023 – Glowing gold, shining silver, and... wheat collusion? In this HotCopper Wire episode, we look at surging gold and silver as well as Trump's appeals court clash, and a wheat futures conspiracy.
Talga back to 50cps on news it's cracked US battery market – with metals recycling shine Shareholders in sometimes troubled graphite player Talga Group have rewarded the company's acumen to move into the U.S. battery anode market.
It's a penny stock buyer's market. Adelong Gold jumps +20% as Nova Mins buys in Adelong Gold, a nanocap and pennystock, jumped +20% in mid-arvo trades after Nova Minerals, also listed on the Nasdaq, bought a 9.4% stake.
Market Close: 4DX Medical finally pulls back; war makes ESG investing cool again Good Afternoon and welcome to HotCopper’s Market Close for Tuesday 9th of September, I’m Jon Davidson. The ASX200 retreated back to the 8,700s intraday as Wall Street finished flattish green overnight leaving little to imagine in terms of bullish sentiment; as of 3...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.